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NF-kB in cellular transformation is well
documented, but how NF-kB contributes
to the initial stages of tumorigenesis is not
clear. Here, Wang et al. show that in pre-
neoplastic cells, the RelA/p65 subunit of
NF-kB functions as a tumor suppressor
by maintaining cells in a senescent state
through the regulation of DNA repair.
However in Ras-expressing cells under-
going transformation, RelA/p65 switches
to an oncogene by protecting tumor cells
from being eliminated by immune surveil-
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NF-kB is considered a major contributor to tumor
development, but how this factor functions in
the initial stages of oncogenesis is not clear. In a
model of Ras-induced transformation, we probed
NF-kB function as preneoplastic cells formed tumors
in mice. As previously shown, the p65 subunit of
NF-kB acts as a tumor suppressor in normal cells
by sustaining senescence following DNA damage.
Our current data reveal that, following immortaliza-
tion, p65 switches to an oncogene by counteracting
the surveillance properties of immune cells. NF-kB
exerts this effect by protecting transformed cells
against macrophage-derived proapoptotic factors,
tumor necrosis factor, and nitric oxide. Additionally,
NF-kB acts through transforming growth factor
beta (TGF-b) to mitigate T cell cytotoxicity and other
factors to expand myeloid-derived suppressor cells.
Together, these data suggest that NF-kB functions in
the early stages of transformation by suppressing
immune surveillance of both innate and adaptive im-
mune cells, information that may be useful for tar-
geted immunotherapies.
INTRODUCTION
Cancer is a complex genetic disease involving multiple steps
of activated proto-oncogenes and inactivation of tumor suppres-
sor genes (Hanahan and Weinberg, 2000). In humans, these
processes take decades, going through stages of tumor initia-
tion, promotion, and progression. This likely explains why the
majority of cancers occur in older adults (Hanahan and Wein-
berg, 2000). In mammals, normal cells experience constant
genotoxic stresses, which lead to DNA damage and genomic
instability. In response to those stresses, tumor suppressors
are activated to mediate proliferation arrest, DNA repair, cellular
senescence, or cell death, which function as intrinsic barriers
against further genetic mutations and tumor initiation (Campisi,90 Cell Reports 9, 90–103, October 9, 2014 ª2014 The Authors2013; Lowe et al., 2004). In the case of cellular senescence,
studies indicate that activated oncogenes trigger a senescence
program rather than directly inducing transformation. Further
loss of tumor suppressors allows cells to escape senescence
and transition to an immortalized state that in the presence of
additional genetic alterations can progress to cancer (Campisi,
2013; Collado and Serrano, 2010).
However, once cells become transformed, they still need to
overcome an extrinsic tumor suppressive mechanism coordi-
nated by innate and adaptive immune cells. These cells function
to detect tumor antigens, derived frommutated or aberrantly ex-
pressed gene products during tumor initiation and progression.
Antigen recognition activates the immune system, leading to
the elimination of tumor cells, a process referred to as immune
surveillance (Pardoll, 2003; Schreiber et al., 2011). Because
cancerous cells are genetically unstable, a rare subset may sur-
vive the elimination phasewhose expansion is kept in equilibrium
with the continued presence of the immune system. Over time,
additional genetic changes allow selected cells to acquire the
ability to circumvent the immune barrier and develop into a fully
cancerous state (Khong and Restifo, 2002; Schreiber et al.,
2011). The capacity for early stage tumor cells to escape immune
surveillance is in fact now considered as a principle hallmark of
cancer (Hanahan and Weinberg, 2011).
As a ubiquitously expressed transcription factor, NF-kB
is widely considered to play a major role in tumor develop-
ment by promoting cell survival, proliferation, angiogenesis,
and metastasis (Chaturvedi et al., 2011; Karin et al., 2002).
Such activities are mediated through homo- or heterodimeriza-
tions of NF-kB subunits RelA/p65, c-Rel, RelB, p50, and p52,
in which RelA/p65 and p50 are the most abundant subunits in
vertebrates. These subunits share a Rel homology domain for
DNA binding, protein interaction, and nuclear localization, but
only RelA/p65 (here on referred to as p65), c-Rel, and RelB
contain additional transactivation domains (Hayden and Ghosh,
2008).
In malignant cells, NF-kB is activated by the oncogenes Ras,
HER2/neu, BCR-ABL, CARD11, and Bcl-10 (Chaturvedi et al.,
2011; Mayo et al., 1997; Reuther et al., 1998; Staudt, 2010).
Gene loci encoding c-rel, NFKBIA, B cell receptor, and A20
also undergo amplifications, mutations, or deletions, which
further accounts for constitutive NF-kB activity (Chaturvedi et al.,
2011; Staudt, 2010). NF-kB antagonizes p53 (Tergaonkar et al.,
2002) and studies support the requirement of NF-kB in breast
cancer and in inflammation-induced oncogenesis (Karin, 2009;
Sovak et al., 1997). In spite of this overwhelming evidence that
NF-kB acts as a tumor promoter, a growing number of reports
indicate that NF-kB also possesses tumor suppressor activity.
NF-kB is capable of inducing the proapoptotic gene CD95/Fas
(Chan et al., 1999), and, in certain tissues such as keratinocytes,
NF-kB promotes growth arrest through regulation of the p21-cy-
clin-dependent kinase inhibitor (Dajee et al., 2003; Seitz et al.,
1998). In addition, conditional deletion of the NF-kB-activating
kinase complex subunits IKKb or NEMO in mice facilitates the
development of heptocellular carcinoma (Luedde et al., 2007;
Maeda et al., 2005).
How NF-kB possesses these seemingly opposite activities
during tumor development remains elusive. One possibility is
that either its tumor suppressor or tumor promoter activity is
restricted to one cell type, as seen in keratinocytes (Dajee
et al., 2003) or colon cells, respectively (Schwitalla et al., 2013;
Shaked et al., 2012). Alternatively, NF-kB may function in a cell
autologous manner, acting both as a tumor promoter and sup-
pressor. To test these possibilities, we utilized a genetic model,
which allowed us to study NF-kB function throughout the early
stages of tumorigenesis. Our findings reveal that precancerous
cells lacking p65 escape senescence and immortalize at a faster
rate compared to wild-type cells. However, during a transition
from immortalization to transformation mediated by Ras, NF-
kB switches from a tumor suppressor to a tumor promoter.
This switch allows Ras-expressing cells to overcome elimination
by the innate and adaptive immune systems. Thus, in addition
to the well-studied antiapoptotic activity of NF-kB (Finco et al.,
1997; Hanson et al., 2004; Mayo et al., 1997), our current work
highlights that during tumor initiation NF-kB protects trans-
formed cells against a suppressive mechanism mediated by
immune surveillance.
RESULTS
p65Acts as a Tumor Suppressor in PrecancerousMouse
Embryonic Fibroblasts
Previous results showed that p65 acts as a tumor suppressor in
cytogenetically normal mouse and human fibroblasts by regu-
lating genomic stability through DNA repair (Rovillain et al.,
2011; Wang et al., 2009). Consistent with these results, we
observed that primary p65/ mouse embryonic fibroblasts
(MEFs) escaped senescence and transitioned into a precancer-
ous, immortalized state considerably faster than p65+/+ litter-
mate cells (Figure 1A). This phenotype associated with defects
in DNA repair, as measured by a delay in g-H2AX recovery
following a sublethal dose of irradiation (4–8 Gy) in p65/
compared to p65+/+ cells (Figure S1A). In addition, DNA dam-
age as assessed by comet analysis exhibited a persistent tail
in p65/ cells (Figure S1B). This equated to 20% DNA strand
break repair in null cells compared to 70% repair in p65+/+ cells
(p < 0.0001) (Figure S1C). Such data reaffirm our original findings
(Wang et al., 2009) and support that NF-kB functions as a tumor
suppressor by maintaining the genomic integrity of primary cells.NF-kB Switches to a Tumor Promoter in
Ras-Expressing MEFs
Next, we asked if loss of tumor suppressor activity in immortal-
ized p65/ cells was sufficient to promote transformation. Pro-
liferation assays revealed that five out of seven p65/ lines
grew at an accelerated rate compared to p65+/+ littermate pairs
(Figure 1B). In addition, p65/ lines readily formed colonies in
soft agar, whereas no colonies were observed in wild-type cells
(Figure 1C). However, in spite of these tumorigenic features,
none of the seven p65/ lines that we established formed tu-
mors in severe combined immunodeficiency (SCID) mice, even
after 10 months of observation (Figure 1D). Thus, although p65
maintains tumor suppressor activity in preneoplastic cells, loss
of this NF-kB subunit is not sufficient to promote tumorigenesis
in mice.
To further understand the role of NF-kB in the early stages
of tumor development, we transformed MEFs with stable
expression of mutant Ha-RasG12V (referred to as p65+/+Ras
and p65/Ras) (Figure 1E). Similar to immortalized cells,
p65/Ras lines maintained a faster doubling time (Figure 1F).
However, in contrast to p65+/+Ras cells that formed tumors as
early as 5–7 days postinjection in 16/16 SCID mice with as little
as 1 3 105 injected cells, tumor onset from p65/Ras cells
was substantially delayed, appearing only after 15–25 days in
15/16 mice (p < 0.004) (Figures 1G and 1H). Similar results
were observed in C57BL/6 nudemice (Figure S1D). Thus, as pre-
viously demonstrated, oncogenic Ras requires NF-kB to facili-
tate tumorigenesis (Finco et al., 1997; Meylan et al., 2009). Taken
together, these results suggest that p65 is capable of switching
activities from a tumor suppressor in normal cells to a tumor
promoter in transformed cells.
NF-kB Protects Transformed Cells from
Macrophage-Induced Cell Death
Mechanistically, how Ras utilizes NF-kB to facilitate tumorigen-
esis remains unclear. To gain insight, we histologically analyzed
p65/Ras tumors that had eventually formed in SCID mice.
Consistent with the notion that cancer development is accom-
panied by active changes in the stroma (Mueller and Fusenig,
2004), host cellular infiltrates were observed that stained posi-
tive for p65 (Figure 2A). Similarly, cells positive for the macro-
phage marker, F4/80, were also observed in these tumor sec-
tions (Figure 2B). This indicated that tumor development is
accompanied by active recruitment of innate immune cells,
which still occurs in SCID and nude mice lacking adaptive im-
munity. Given that tumor development from p65/Ras cells
was delayed in SCID and nude mice, we considered that this
lag derived from infiltrating macrophages (MFs) that functioned
in surveillance to eliminate Ras-transformed cells lacking NF-
kB. To test this notion, we probed for the presence of MFs
following peritoneal injections of p65+/+Ras or p65/Ras cells
in SCID mice. After only 5 days, infiltrating immune cells were
clearly detected, of which >90% were MFs (Figures S2A and
2C). Next, SCID mice were treated with liposomes containing
the chemical, clodronate, which depletes MF (Figure S2B).
This treatment caused adverse effects in SCID mice (likely
due to a highly compromised immune system; Movie S1). How-
ever, from the mice that survived, we observed that p65/RasCell Reports 9, 90–103, October 9, 2014 ª2014 The Authors 91
Figure 1. NF-kB Is Able to Switch from a
Tumor Suppressor to a Tumor Promoter
(A) Primary p65+/+ and p65/ cells were sub-
cultured every 3 days until immortalization. Graph
depicts cumulative cell numbers at each passage
(n = 3).
(B) Immortalized p65+/+ and p65/ MEFs were
inoculated and counted at indicated time points.
Data are represented as mean ± SD from five out
of seven pairs of immortalized lines.
(C) Same cells in (B) were grown in soft agar and
colonies (>40 cells/cluster) were subsequently
scored. Data are represented as mean ± SD from
three independent experiments.
(D) Immortalized p65+/+ orp65/ cells (1 3 107)
were subcutaneously injected into SCID mice.
Mice were photographed after 10 months, and
data are representative of a minimum of ten mice
per group that were injected with either p65+/+ or
p65/ cells.
(E) Western blotting was performedwith a pan Ras
antibody on cell extracts from immortalized p65+/+
and p65/ cells infected with pBabe-Hygro or
pBabe-H-RasG12V retroviruses.
(F) p65+/+Ras or p65/Ras cells were inocu-
lated, and at indicated time points cells were
counted. Data are representative of mean ± SD
from three out of four pairs of Ras-expressing
lines.
(G and H) To compare tumor growth, p65+/+Ras
and p65/Ras cells were injected in SCID mice
on left and right flanks, respectively. Photographs
were taken after 4 weeks (G) or tumor sizes were
measured at indicated time points and tumor
diameter was plotted (H). Data are representative
of at least 16 mice injected in three independent
experiments (p = 0.004).tumors formed faster than in control mice treated with PBS/lipo-
somes (Figure 2D; p < 0.0001). In contrast, p65+/+Ras cells
showed a significantly delayed tumor growth (Figure S2C; p =
0.0338). These data highlighted a function of NF-kB in an92 Cell Reports 9, 90–103, October 9, 2014 ª2014 The Authorsearly stage of tumor development that
provides transformed cells resistance
against innate immunity.
We then determined how NF-kB
was required for this resistance. We
designed an experiment where an
equivalent number of p65+/+Ras and
p65/Ras cells were ‘‘painted’’ with
fluorescent tracker dyes, CMRA (orange)
and CFSE (green), respectively, and
mixed together in culture. This mixed
population was subsequently cocultured
with increasing ratios of activated MF.
Following an overnight incubation, these
cells were fixed and analyzed by fluo-
rescence microscopy to score for
viability based on how many CMRA+
and CFSE+ cells remained on the plate.
Compared to p65+/+Ras cells, which re-mained viable with increasing ratios of MF, p65/Ras viability
was pronouncedly reduced (Figures 3A and S3A), showing that
Ras-transformed cells lacking NF-kB are sensitive to MF-in-
duced killing.
Figure 2. p65/Ras Tumors Show Host
Immune Cell Infiltration
(A and B) Tumors arising in SCID mice from
p65+/+Ras and p65/Ras cells were sectioned
and subsequently stained immunohistochemically
for p65 (A) or F4/80 (green) counterstained with
DAPI (blue) (B).
(C) p65+/+Ras and p65/Ras cells were injected
peritoneally into SCID mice and infiltrating cells
were harvested after 5 days and quantitated for
F4/80 staining by FACS. Data were plotted as
mean ± SD from two independent experiments
with at least fourmice in each group. Both total cell
and MF numbers were compared to the PBS
group: *p < 0.01; **p < 0.0005.
(D) Once per week, clodronate/liposome or its
carrier, PBS/liposome were injected intrave-
nously via tail vein. Two days after first injections,
p65/Ras cells were injected subcutaneously
into SCID mice. At indicated time points, tumor
size wasmeasured and plotted by tumor diameter.
Data are representative of three independent ex-
periments (p < 0.0001).Because MFs are a major source of tumor necrosis factor
(TNF), which in the absence of NF-kB functions as a potent pro-
apoptotic factor (Gapuzan et al., 2005), we investigated whether
elimination of p65/Ras cells was dependent on this cytokine.
Therefore, p65+/+Ras and p65/Ras cells were cocultured
with increasing ratios of MF derived from TNF/ mice.
Compared to wild-type MF, those deficient in TNF were signifi-
cantly less toxic to p65/Ras cells, although toxicity was still
observed (Figure 3B). These data supported that Ras cells
require p65 to survive the proapoptotic activity of TNF produced
from MF.
We then employed an MTS strategy to screen for additional
proapoptotic factors secreted from MF, including interleukin
(IL)-12, IL-15, IFN-b, H2O2, and nitric oxide (NO). Regardless of
dose, IL-12, IL-15, IFN-b, and H2O2 had little effect on the
viability of p65+/+Ras or p65/Ras cells (Figures S3B–S3E).
However, addition of the NO donor, sodium nitroprusside
(SNP), was extremely potent in eliminating p65/Ras cells (Fig-
ure 3C). Given that NO is generated by inducible nitric oxide syn-
thase-2 (iNOS), we addressed the role of iNOS in MF-mediated
killing of p65/Ras cells by coculturing Ras-transformed cells
withMF in the presence or absence of the iNOS inhibitor, amino-
guanidine. Compared to untreated MF, those exposed to ami-
noguanidine were significantly less effective at eliminating
p65/Ras cells (Figure S3F). Similarly, MFs from iNOS/
micewere equally less potent in eliminating p65/Ras cells (Fig-
ure 3D). Importantly, p65/Ras cells were completely resistant
to MF lacking both iNOS and TNF (DKO) (Figure 3E). We furtherCell Reports 9, 90–10used fluorescence-activated cell sorting
(FACS), and markers of apoptosis (An-
nexin V) and necrosis (7-AAD), to deter-
mine the mechanism of MF-mediated
cell killing. Although some level of necro-
sis was observed, themajority of killing by
TNF + NO or activated MF derived fromapoptosis (Figure 3F). Moreover, measurement of NF-kB antia-
poptotic genes revealed that c-IAP1/2, and to a lesser extent,
BCL-XL and BCL-2, were reduced in p65/Ras compared to
p65/Ras cells (Figure S3G). Together, these data suggest
that in the initial stages of Ras transformation, infiltrating MFs
participate in tumor elimination by secreting cytotoxic factors
TNF and NO, but this surveillance property can be circumvented
by the antiapoptotic activity of NF-kB in tumor cells.
p65/Ras Cells Are Genetically Unstable, Leading to
Tumor Formation
Having shown that Ras cells lacking NF-kB are sensitive to
innate immune cells, and that this sensitivity leads to a delay in
tumor onset, we next asked why transplanted p65/Ras cells
were eventually able to overcome the surveillance property of
MFs and develop tumors as seen in Figures 1G and S1D. To
address this point, we surgically removed tumors developed in
SCID mice and reconstituted p65+/+Ras and p65/Ras cells in
culture under selection to eliminate any host cell contaminants.
Immunoblots confirmed that selected cells, now referred to
as RasT (for tumor derived), maintained an appropriate p65
genotype (Figure 4A). Interestingly, unlike p65/Ras cells,
p65/RasT cells were no longer sensitive to TNF killing (Fig-
ure S4A). Likewise, p65/RasT cells were completely refractory
to increasing ratios of MF and were more resistant to NO-
induced apoptosis (Figures 4B and S4B). This suggested that
p65/RasT cells had developed a mechanism to escape the
surveillance property of MFs.3, October 9, 2014 ª2014 The Authors 93
Figure 3. Ras Cells Lacking p65 Are Sensitive to Innate Immunity-Induced Cell Death
(A) p65+/+Ras and p65/Ras cells were respectively stained with fluorescence dyes, CMRA and CFSE, and then cocultured with activated macrophages (MFs).
Viability was scored by calculating the percentage of CMRA and CFSE-positive cells that remained on the culture dish. Data are representative of three inde-
pendent experiments. *p < 0.001.
(B) p65+/+Ras or p65/Ras cells were incubated with MF, either wild-type or null for TNF, and viability was scored by a trypan blue exclusion assay. Cell survival
was normalized to untreated cells, set to 100%. Data are representative of at least three independent experiments, each from two independent pairs of Ras-
transformed cells. *p < 0.05, **p < 0.04.
(C) p65+/+Ras and p65/Ras cells were incubated with the NO donor SNP at indicated concentrations, and viability was scored with an MTS assay.
(D) Similar as (B) except that MFs were used that were either wild-type or null for iNOS. *p < 0.005, **p < 0.002.
(E) Similar as (B) except that MFs were used that were either wild-type or double null for TNF and iNOS. *p < 0.001, **p < 0.0002.
(F) p65+/+Ras and p65/Ras cells were cocultured with NO plus TNF or with increasing ratios of MFs overnight. Cells were then stained for Annexin V, 7-AAD,
and CD11b. CD11b cells positive for Annexin V or positive for 7-AAD and negative for Annexin V were graphed.
(A–F) Data are represented as mean ± SD. *p < 0.02 is compared to p65+/+Ras cells; **p < 0.02 is compared to p65/Ras cells.
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Figure 4. p65/Ras Cells Reconstituted from p65/Ras Tumors Develop Resistance to Innate Immune Cell-Mediated Cell Death
(A) p65+/+Ras and p65/Ras tumors were surgically removed from SCID mice and reconstituted in culture with antibiotic selection. Lysates were prepared and
westerns performed probing for p65.
(B) p65+/+RasT and p65/RasT cells were cocultured with activatedMF and viability was scored by trypan blue exclusion. Data are represented asmean ± SD of
three independent experiments from two pairs of cells.
(C) Frozen sections from p65+/+ and p65/ tumors were stained with anti-g-H2AX (green) and anti-pBP1 (red). Cell nuclei were counterstained with DAPI (blue).
(D) p65+/+Ras and p65/Ras cells were infected with a pBabe retrovirus expressing LacZ. Cells were stained for LacZ immediately after retrovirus infection or
after 2 weeks of puromycin selection.
(E) Microarray, M-A gene expression plots of p65+/+RasT or p65/RasT cells compared to p65+/+Ras or p65/Ras cells. Red markings denote genes that
have >2-fold expression changes in RasT cells compared to Ras cells.
(F) Histogram representing the number of genes exhibiting significant up or downregulated expression changes between p65+/+RasT and p65+/+Ras or
p65/RasT and p65/Ras cells.
(G) p65+/+RasT and p65-/-RasT cells were injected subcutaneously into SCID mice, and, at indicated times, tumors were measured with a digital caliber and
represented as mean ± SD; p < 0.0001.Cells expressing oncogenes are genetically unstable and are
under continuous immune selection in vivo (Khong and Restifo,
2002). Over time, a rare subset of these cells develop mecha-
nisms to overcome elimination by immune cells, thus allowing
for their expansion (Khong and Restifo, 2002; Schreiber et al.,
2011). Because we showed that cells lacking p65 are com-
promised in DNA repair (Wang et al., 2009) (Figure S1), we hy-pothesized that similar cells in vivo would be susceptible to
continuous genetic insults leading to greater genetic instability
and, in turn, would acquire the ability to evade immune surveil-
lance. To test this notion, frozen sections from p65+/+Ras and
p65/Ras tumors were stained for g-H2AX. Although both tu-
mor types exhibited DNA damage, g-H2AX foci were noticeably
higher in tumors lacking p65 (Figure 4C), which correlated with aCell Reports 9, 90–103, October 9, 2014 ª2014 The Authors 95
second DNA damage repair marker, p53BP1 (Noon et al., 2010).
This indicated that in vivo, p65/Ras tumor cells undergo
augmented genomic alterations. To confirm these results, we
performed a LacZ genomic stability assay, which as shown pre-
viously (Wang et al., 2009), is an effective method to quantita-
tively measure genomic integrity. This assay relies on the stable
integration of a retrovirus expressing the b-galactosidase (LacZ)
reporter gene, which is lost as a result of DNA deletions, muta-
tions, or epigenetic silencing. Results showed that compared
to p65+/+Ras cells, LacZ expression was completely absent in
p65/Ras cells (Figure 4D). Given that retrovirus integration in
mammalian genomes require proper DNA repair (Skalka and
Katz, 2005), our findings suggest that Ras-transformed cells
lacking p65 exhibit higher defects in DNA repair, leading to
increased genomic instability.
Because genetic alterations are commonly reflected by
changes in gene expression, high-density gene expression
profiling was performed between two pairs of populations,
p65+/+Ras versus p65+/+RasT andp65/Ras versus p65/RasT
cells.Consistentwithgenomic stability results,we found that only
300 genes were differentially expressed following the transition
from p65
+/+
Ras to p65+/+RasT cells (Figure 4E). In contrast,
2,000 genes were significantly altered as p65/Ras pro-
gressed top65/RasTcells, and the vastmajority of thesegenes
(>1,900) were upregulated (Figure 4F). Such results demonstrate
that genetic alterations occur at a higher frequency during the
transition from p65/Ras to p65/RasT cells. These data
further indicate that tumor formation from p65/Ras cells in im-
mune-compromisedmice results from inefficient DNA repair and
genomic instability,which, in turn, allows selected cells to escape
the cytotoxic effects of TNF and NO from innate immune cells.
From these results above, we reasoned that p65/RasT cells
should be competent to form tumors in SCID mice because they
had already undergone selection in vivo, making them capable
of overcoming MF-induced cell death. Indeed, not only did
p65/RasT cells overcome the initial delay period in tumor for-
mation seen with p65/Ras cells, but, impressively, tumors also
developed with faster kinetics than those from p65+/+RasT cells
(Figure 4G). Although we showed that p65/RasT cells were
resistant to TNF and NO, we asked whether their selection
in vivo also made them resistant to other proapoptotic activities
mediated by chemotherapeutic compounds. Unlike TNF and
NO, in vitro treatment with, doxorubicin was similarly effective
in killing p65/Ras and p65/RasT cells, as compared to
p65+/+ cells (Figure S4C). In addition, although doxorubicin
administration in mice had no effect on the growth rate of
p65+/+RasT tumors, those same doses caused significant
reduced growth of p65/RasT tumors (Figures S4D and S4E).
Similar results were observed with etoposide (data not shown).
These findings indicate that mutations that arose during the
development of p65/Ras tumors were likely selected for their
resistance against the innate immune system, but not other pro-
apoptotic pathways elicited by chemotherapy.
Ras Cells Lacking p65 Are Completely Inhibited from
Forming Tumors in Immune-Competent Mice
Because our results supported that NF-kB acts in the initiating
stages of oncogenesis to protect transformed cells from MF,96 Cell Reports 9, 90–103, October 9, 2014 ª2014 The Authorswe next asked whether such protection could be extended to
adaptive immune cells. Therefore, we subcutaneously injected
p65+/+Ras and p65/Ras cells into syngeneic C57BL/6 mice,
which unlike SCID or nude mice contain a fully competent
immune system. In striking contrast to wild-type cells, which
readily formed tumors after only 10 days postimplantation,
Ras cells lacking p65 completely failed to form tumors in
100% (30/30) of injected mice, even after 10 months of obser-
vation (Figure 5A; data not shown). This dramatic result under-
scores the pivotal role that NF-kB plays in oncogenic Ras-ex-
pressing cells in evading the surveillance mediated by both
innate and adaptive immune cells. To further test this point,
we took p65/RasT cells, which resist MF-induced cell death
and injected them into immune-competent C57BL/6 mice.
Although p65/RasT cells were capable of initially forming
tumor nodules in the first 10 days postinjection, these nod-
ules completely regressed between 16 and 20 days, and
no further tumor formation was observed in 97% (29/30) of in-
jected mice, as compared to tumors that rapidly formed from
p65+/+RasT cells (Figure 5B and inset; Figure S5). We suspected
that this initial growth of p65/RasT tumors at 10 days postin-
jection reflected cells that were resistant to activated MF but
were eventually eliminated by adaptive immune cells. To
confirm this notion, C57BL/6 mice were preimmunized by injec-
tion of p65/Ras cells, and after 2 weeks further injected with
p65/RasT cells. Compared to nonimmunized mice where in-
jection of p65/RasT cells were observed to again induce tu-
mor nodules that subsequently regressed, those preimmunized
were completely unable to form tumors (Figure 5C). These re-
sults strongly suggest that NF-kB functions in transformation
as a regulator of immunoevasion from both innate and adaptive
immune systems.
NF-kB Promotes Ras Tumor Initiation by Overcoming
Adaptive Immunity
Because tumor cells are known to express antigens that are
recognized by immune cells to mediate tumor surveillance
(Schreiber et al., 2011), we considered the possibility that NF-
kB functioned to evade adaptive immunity by circumventing
the expression of surface antigens recognized by cytotoxic T
lymphocytes (CTLs). To test this prediction, we first irradiated
p65+/+Ras and p65/Ras cells with X-ray (50 Gy) to suppress
their growth, and then syngeneic C57BL/6mice were immunized
by injecting these cells. Two weeks later, splenocytes were iso-
lated and antigen specific CTLs were expanded by coculturing
with growth arrested p65+/+Ras or p65/Ras cells as immu-
nogen. Results showed that these enriched CTLs exhibited
extremely strong killing activity that did not discriminate between
p65+/+ and p65/ status (Figure 5D). This immune responsewas
specific to p65 Ras cells because considerably less T cell cyto-
toxicity was observed with HeLa or 293T cells, used as controls
(Figure 5E). These data indicate that Ras cells expressing p65
remain immunogenic, and thus susceptible to T cell-mediated
killing.
To explore what other mechanisms are responsible for allow-
ing p65+/+Ras cells to develop tumors in the presence of an
adaptive immunity, we reanalyzed our high-density profiling
data and noticed that several known immune suppressor genes
Figure 5. p65 Mediates Immune Tolerance
(A) p65+/+Ras and p65/Ras cells were injected subcutaneously into C57BL/6 mice and tumors were measured at indicated time points.
(B) p65+/+RasT and p65/RasT cells were injected subcutaneously into C57BL/6 mice and similar to (A) tumors were measured with a digital caliber.
(C) PBS (No preimmunization) or p65/Ras cells (Preimmunized) were injected in the right flank of C57BL/6 mice. Two weeks later, p65/RasT cells were
injected in the left flank of the same mice. Tumor size was measured at the times as shown in (C).
(D) p65+/+Ras and p65/Ras cell-specific CTLs were obtained as described in Experimental Procedures and subsequently cocultured with p65+/+Ras or
p65/Ras cells at indicated CTL:Target ratios. After 36–48 hr, cell viability was determined by trypan blue exclusion.
(E) Similar to (D) with the exception that HeLa and 293T cells were used and cocultured with primed CTLs.
In (C)–(E), data are represented as mean ± SD.were downregulated in p65/Ras cells, including transforming
growth factor beta (TGF-b), IL-10, GM-CSF, G-CSF, and
VEGF. This regulation was validated by qualitative RT-PCR (Fig-
ure 6A), suggesting that these genes are regulated by NF-kB in
Ras-transformed cells. This was confirmed by first showing
that these genes were induced by an NF-kB-activating signal
(Figure S6A), and second, by demonstrating that inhibition of
NF-kB by stable expression of the IkBa-SR in p65+/+Ras cells
led to a reduction in TGF-b, IL-10, GM-CSF, G-CSF, and VEGF
(Figures S6B and S6C). TGF-b and IL-10 are considered immune
suppressive cytokines that inhibit dendritic cell maturation and
CTL function (Vesely et al., 2011), whereas GM-CSF, G-CSF,
and VEGF exhibit immunosuppressive activity by stimulating
myeloid derived suppressor cells (MDSCs) to diminish CTL-
mediated immune surveillance (Vesely et al., 2011). Thus,
NF-kB appears capable of coordinating a network of immune
suppressor genes whose products are important for tumor cells
to evade adaptive immunity.
We tested the contribution of one of these immune suppres-
sor genes, TGF-b, by systemically treating mice with injected
p65+/+Ras cells with a monoclonal antibody for this factor.
Neutralization of TGF-b had little effect on the initiation of
tumors during the first 10 days of treatment, which supports
our earlier conclusion that adaptive immune cells are not fullyactive during this early phase of tumor development (Figure 6B).
However, shortly afterward, tumor growth was significantly
delayed, and survival considerably improved, in mice treated
with anti-TGF-b compared to immunoglobulin (Ig) G control
(Figures 6B and 6C). Next, we tested the direct contribution
of TGF-b from p65+/+Ras cells by generating cell lines stably
expressing a TGF-b-silencing shRNA. Two clones (p65+/+Ras-
shTGF7 and p65+/+Ras-shTGF10) that contained efficient
knockdown of TGF-b mRNA and protein (Figures S6D and
S6E) were further examined for their effects on tumor initiation.
Results showed that tumor development was delayed from
both injected p65+/+Ras-shTGF7 and p65+/+Ras-shTGF10
clones compared to vector control lines, p65+/+Ras-V2 and
p65+/+Ras-V4 (Figures 6D and 6E as averaged values). Together,
these data support the notion that TGF-b represents at least one,
among multiple, NF-kB-regulated genes that contributes to the
development of Ras tumors.
NF-kB Activation in Transformed Cells Shows Enhanced
MDSC Mobilization
MDSCs and T regulatory cells (Treg) represent two major cell
types in the immunosuppressive network (Schreiber et al.,
2011; Vesely et al., 2011). To investigate if the increase in GM-
CSF, G-CSF, and VEGF in p65+/+Ras cells induce the productionCell Reports 9, 90–103, October 9, 2014 ª2014 The Authors 97
Figure 6. p65-Regulated TGF-b Is Responsible for Tumor Immune Tolerance
(A) Validation of immune suppressive genes from microarray analysis from Figure 4E was performed with real-time RT-PCR. Data are plotted as mean
expression ± SD for each gene. All *p < 0.001.
(B) p65+/+Ras cells were injected subcutaneously into C57BL/6 mice and 2 days postinjection mice were administered a monoclonal antibody against TGF-b
(a-TGF-b) or rat IgG (IgG) via tail vein once per week. Tumor growth was measured at indicated time points. Arrowheads indicate the times when anti-TGF-b
antibody was injected. Data are representative of mean tumor sizes ± SD from two independent experiments. p < 0.05.
(C) Similar to (B), except that the survival of mice was recorded.
(D and E) p65+/+Ras cells were infected with a lentivirus expressing GFP (V) or shRNA against TGF-b (shTGF). Indicated cell lines with confirmed TGF-b
knockdown were injected into C57BL/6 mice, and tumor size wasmeasured compared to vector control lines, graphed separately (D) or as averaged values ±SD
(E, shVector: p = 0.22; shTGF-b: p = 0.025).
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of immunosuppressive cells, splenocytes were isolated from
C57BL/6 mice injected with p65+/+Ras and p65/Ras cells
and subsequently stained with appropriate antibodies against
markers of MDSC and Tregs. Results showed that as early as
9 days postinjection, tumor growth from p65+/+Ras cells was
accompanied with a significant increase in MDSCs (CD11b+;
Gr-1+) compared to injected saline control or p65/Ras cells
(p < 0.005) (Figures 7A and 7B). In contrast, no differences in
the number of Tregs (CD4+; CD25+; Foxp3+) were observed at
this stage of tumor development (Figures S7A–S7C). To further
examine the regulation of MDSCs by NF-kB, bone marrow
(BM) cells were isolated from C57BL/6 mice and cocultured
with p65+/+Ras or p65/Ras cells. After 6–7 days, a significantly
higher number of MDSCs were observed from BM cells cocul-
tured with p65+/+Ras compare to p65/Ras cells (Figures 7C
and 7D). Similarly, MDSCs were also expanded from BM cells
in the presence of conditioned media from p65+/+Ras (Figures
7E and S7D), but this expansion was reduced when conditioned
media was incubated with antibodies against GM-CSF, G-CSF,
or VEGF (Figure S7E). These data suggest that NF-kB regulates
the production ofMDSCs through a combination of target genes,
GM-CSF, G-CSF, and VEGF. Because MDSCs participate in an
immunosuppressive network by mitigating a T cell response, we
next asked if the regulation of MDSCs by NF-kB-affected T cells.
Therefore, T cells were isolated and stimulated by CD3/CD28
antibodies, and proliferation of CD4+ and CD8+ T cells wasmoni-
tored in cocultures with MDSCs obtained from mice injected
with p65+/+Ras cells. Compared to control conditions, cultures
containing MDSCs caused a significant growth defect in both
CD4+ and CD8+ T cells (Figures 7F and 7G), suggesting that
MDSCs derived from p65+/+Ras-injected mice are capable of in-
hibiting T cell activation. To further evaluate this regulation in vivo,
p65/RasT cells were injected subcutaneously into C57BL/6
mice (cohort 1). Two days postinjection, MDSCs, isolated from
a separate cohort of mice preinoculated with p65+/+Ras cells
for 14–16 days (Figure S7F), were administered intravenously
once per week into cohort 1, and tumor initiation was subse-
quently monitored. Compared to mice without MDSC adminis-
tration, where tumors completely regressed, mice injected with
p65/RasT cells receiving weekly doses of MDSCs showed
significantly higher tumor growth that was sustained even after
40 days of observation (Figure 7H). Such results support the
conclusion that NF-kB-mediated transcription regulates MDSC
production to promote tumor initiation by evading the surveil-
lance of adaptive immune cells.
DISCUSSION
Results in this study highlight several key points about how NF-
kB functions in the initial stages of tumor development. One is
that p65 is capable of switching from a tumor suppressor to a tu-
mor promoter based on the staging of tumorigenesis. Previous
studies have postulated that NF-kB can possess tumor suppres-
sor activity (Chaturvedi et al., 2011; Perkins, 2004), but such
function has not been shown to change over time based on
the genetic background of the cell. In contrast, our results sug-
gest that this regulation can occur in a cell autologous manner.
Although Ras was used to drive oncogenesis in this study, thefact that NF-kB is activated by a variety of oncogenic signaling
pathways (Chaturvedi et al., 2011; Mayo et al., 1997; Reuther
et al., 1998; Staudt, 2010) suggests that the decision for NF-kB
to switch from a tumor suppressor to a tumor promoter is likely
to be regulated by more than Ras.
A significant feature of cancer development involves the inter-
play between tumor cells and surrounding stroma (Mueller and
Fusenig, 2004). MFs are immune cells that play multifaceted
roles in the initiation and progression, as well as the immune
tolerance of tumor cells (Allavena et al., 2008; Qian and Pollard,
2010). Previous studies indicated that NF-kB maintains an
intrinsic cell survival property, which is important for Ras-medi-
ated oncogenesis (Finco et al., 1997; Hanson et al., 2004;
Mayo et al., 1997). In addition to these reports, our current find-
ings show that NF-kB is required to protect transformed cells in
their initial stage of tumor growth from MF-induced apoptosis,
mediated through secretion of TNF and NO. Such results signify
a key role that NF-kB plays between cancer cells and an inflam-
matory microenvironment.
Our results also showed that the link between NF-kB and
tumorigenesis extends to adaptive immunity. Whereas trans-
plantation of p65/Ras and p65/RasT cells into immune
compromised mice develop tumors, these same lines, no matter
how genetically unstable, were unable to form tumors when
transplanted into mice with a fully competent immune system.
This is in dramatic contrast to p65+/+Ras and p65+/+RasT where
tumors readily formed in mice irrelevant of lymphocyte status.
Cancer cells have long been considered to be immunogenic,
and their survival is continuously threatened by immune surveil-
lance (Pardoll, 2003; Schreiber et al., 2011), a point that was
recently reaffirmed in a K-Ras mouse model of sarcoma, as
well as through the identification of the tumor antigen, spec-
trin-b2 (DuPage et al., 2012; Matsushita et al., 2012). Studies
also indicate that NF-kB activation promotes antigen presenta-
tion of advanced Lewis lung carcinoma cells (Hopewell et al.,
2013). However, in our model, NF-kB did not compromise anti-
gen expression because both p65+/+Ras and p65/Ras cells
were equally sensitive to CTL-mediated killing. Rather, our
results support that Ras requires NF-kB to mediate an im-
mune-tolerant environment through the expression of multiple
immunosuppression genes that separately or together coun-
teract surveillance properties of adaptive immune cells by
increasing the population of MDSCs. Thus, in addition to the
previously well-described antiapoptotic activity of NF-kB in
response to Ras (Hanson et al., 2004; Mayo et al., 1997), we pro-
pose that an added vital function of NF-kB in cancer is to provide
developing tumors the ability to circumvent elimination from im-
mune surveillance. Because these factors are regulated by NF-
kB, and TNF is a potent activator of NF-kB, it is also possible
that TNF secreted from infiltrating MFs could play some role
regulating the immunoevasive property of NF-kB against adap-
tive immunity. Importantly, our findings are distinct from the
interplay previously described in prostate cancer, where in
that scenario NF-kB was activated in epithelial cells by B lym-
phocytes to stimulate cell proliferation and maintain stem cell
renewal necessary for tumor recurrence (Ammirante et al.,
2010). Recently, investigators demonstrated that overexpres-
sion of IKKb in lung epithelium promotes the accumulation ofCell Reports 9, 90–103, October 9, 2014 ª2014 The Authors 99
Figure 7. p65-Regulated Genes Are Responsible for Increased MDSC Mobilization
(A) FACS results of splenic cells from C57BL/6 mice 7–10 days after injecting PBS, p65+/+Ras or p65/Ras cells. MDSCs are identified as CD11b/Gr-1 double-
positive cells.
(legend continued on next page)
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Tregs (Zaynagetdinov et al., 2012). Such findings, in combination
with our current results, highlight the multiple signaling interac-
tions that occur between tumor and surrounding immune cells.
Even after decades of intensive efforts, progress to develop
effective tumor immunotherapies has been hampered by the
ability of cancer cells to develop diverse strategies to overcome
elimination by innate and adaptive immune cells (Alpizar et al.,
2011; Zou, 2005). Our results reveal that NF-kB appears to
play a pivotal role in tumor immune tolerance, because trans-
formed cells lacking NF-kB are completely incapable of forming
tumors in immune competent mice. Although certain factors
have been identified as mediators of immune tolerance, the un-
derlying mechanisms of immune surveillance evasion remains
unclear. We believe our findings are significant for they point to
NF-kB as a possible Achilles’ heel of cancer cells. If this is the
case, current immunotherapy in combination with NF-kB inhibi-
tion may be considered an effective strategy to treat cancer.
EXPERIMENTAL PROCEDURES
Cell Survival Assays
For cell painting analysis, 106 Ras cells were washed and stained in PBS
0.05% BSA with CMRA (orange, for p65+/+Ras cells) or CFSE (green, for
p65/Ras cells) fluorescence dyes according to the manufacturer (Invitro-
gen). Stained cells were then mixed in a 1:1 ratio and applied to 35 mm dishes
containing coverslips. Two hours later, isolated MFs were applied and incu-
bated at 37C with 5% CO2 for an additional 16–20 hr. Cells were fixed with
4% paraformaldehyde in PBS and mounted onto slides with DAPI-containing
mounting solution (Electron Microscopy Sciences). Mounted cells were then
observed with a fluorescence microscope and red to green cell ratios were
calculated. For apoptosis analysis, cells were coincubated with harvested
MFs overnight. The next day, cells were harvested by trypsinization and
stained with FITC-rat anti-mouse CD11b (BioLegend). Then cells were washed
with Annexin V staining buffer and stained for Annexin V and 7-AAD with an
phycoerythrin (PE) conjugate Annexin V staining kit (BD Pharmingen) as rec-
ommended by the manufacturer and analyzed by FACS. For CTL assays,
p65+/+Ras or p65/Ras cell-specific CTLs were prepared (Supplemental
Experimental Procedures) and cocultured with tumor cells in 96 well plates
with 5–10 units/ml of IL-2. Thirty-six to 48 hours later, plates were trypsinized
and viable cells were counted by a trypan blue exclusion assay.
T Cell Activation Analysis
T cells were isolated from spleens of C57BL/6mice using amurine T cell nega-
tive isolation kit (Invitrogen). Isolated T cells were then stained with 5 mM of
CFSE and subsequently activated by coculturing with CD3/CD28 magnetic
beads (Invitrogen) with or without MDSCs. Forty-eight hours later, cells were(B) From data in (A), percentages of MDSCs in mouse spleens were graphed as
least three mice injected (*, **p < 0.005).
(C) Bone marrow cells were cocultured with either p65+/+Ras or p65/Ras cells. A
describe in (A).
(D) From data in (C), the percentage of MDSCs was calculated. Data are represe
(E) Bone marrow cells were either incubated with conditioned media from p65+/+R
10 ng/ml GM-CSF as control for 6 days. The same as in (C), but cells were harveste
independent experiments. *p < 0.001.
(F) CFSE-stained T cells isolated from C57BL/6 spleens were activated by culturi
isolated from p65+/+Ras-injected mice. Two to 3 days later, cultured cells were h
(G) Percentages of CD8+ or CD4+ cells with lower fluorescence intensity than T
growth. * and **p < 0.0001. Data are represented as mean percentage of T cell g
(H) p65/RasT cells were injected subcutaneously into two groups of C57BL/
p65+/+Ras-injected mice (days 14–16). PBS (C) or isolated MDSCs (MDSC) were
heads). At indicated time points, tumor sizes were measured with a digital calibeharvested and fixed for 30 min on ice in 2% paraformaldehyde/PBS. Fixed
cells were then stained with PE-conjugated rat anti-CD8 and APC/Cy7-conju-
gated rat anti-mouse CD4 monoclonal antibodies, which were then analyzed
by FACS.
Macrophage Depletion, TGF-b Neutralization, and MDSC Treatment
Treatments were carried out by intravenous injections via tail vein with at a
dose of 100 ml/10 g body weight of mice. For MF depletion, clodronate/lipo-
some or PBS/liposome was vortexed vigorously before injection. Rat-anti-
TGF-b (BioLegend) was diluted with PBS at 20–50 mg/200 ml before injection.
For MDSC isolation, p65+/+Ras cells were injected subcutaneously into
C57BL/6 mice. Ten to sixteen days after injections, MDSCs were separated
from spleen and surrounding lymph nodes with an MDSC isolation kit (Miltenyi
Biotec). MDSCs purity was confirmed by staining a small portion of isolated
cells with fluorescent antibodies against CD11b and Gr-1, and verifying by
FACS (Figure S7F). At the arranged time point, p65/RasT cells were also in-
jected subcutaneously into C57BL/6 mice. Two days after tumor cell inocula-
tion, isolated MDSCs were resuspended in PBS at 5–8 3 106 cells/200 ml and
subsequently injected intravenously in mice once per week.
Statistical Analysis
For tumor growth analysis, an analysis of variance (ANOVA) approach was
adopted to analyze differences between each group. Student’s t tests were
used for all other analysis.
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